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Abstract
Objectives: The irrational use of reserved antimicrobials, such as ceftriaxone, is one of the global public health
issues particularly to low income countries like Ethiopia, leading to high costs of treatment or therapeutic failure.
The purpose of the present study, thus, is to evaluate the appropriateness of ceftriaxone utilization in the medicine
wards of general hospitals in Addis Ababa, with reference to the standard treatment guideline of Ethiopia for
general hospitals.
Methods: An institution based retrospective cross sectional study design was conducted in the internal medicine
wards of Hayat and Zewditu Memorial hospital from 20 January to 20 February, 2014. Medication records of all
patients who were admitted and prescribed with ceftriaxone during the previous one year to the study period
were evaluated in reference to the Ethiopian Standard Treatment Guideline (STG 2010) for general hospitals.
Results: The proportion of patients who received ceftriaxone was 59.3 % and 49 % in the public & the private
hospital, respectively. Pneumonia, meningitis and sepsis were the common diagnoses in which ceftriaxone was
prescribed in both hospitals. Maintenance fluids were the top ranked co-prescribed drugs in either hospital. Only
48.9 % in the public hospital and 44.6 % of records in the private hospital showed overall ceftriaxone use
compliance to the guideline. Days of hospital stay was associated with appropriateness of ceftriaxone therapy.
Conclusions: Even though ceftriaxone is one of the most commonly prescribed drugs in both hospitals, appropriateness
of its use, according to the Ethiopian standard treatment guideline, was less than expected. This was so mainly
from its indication and duration of therapy. Increasing the duration of hospital stay, however, showed to improve
the appropriateness of ceftriaxone utilization.
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Introduction
Antimicrobials have played a remarkable role in public
health through decreasing of morbidity and mortality
[1]. The 19th and 20th are a particular centuries when
longevity and health of populations progressed as the
result of substantial achievements in controlling infec-
tious diseases [1, 2]. This, however, was not without
any challenge. Anti-microbial resistance (AMR) due to
the over use of the reserved antibiotics is one of the
threatening global issues of public health [3–5]. Many
patients suffer due to harms arising from AMR because
the infections caused by viruses, bacteria, fungi, proto-
zoa and helminthes are no longer susceptible to the
commonly available antibiotics. As a result, several
stakeholders at every corner are striving to stimulate
policies and actions in the healthcare system. As em-
phasized in a report by WHO, the Possible conse-
quences that may arise include loss of productivity (loss
in income, diminished worker productivity, time spent
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by family) and increased cost of diagnostics and treat-
ment (consultation, infrastructure, screening, cost of
equipment and drugs). In the same instance, while both
the health and economic consequences of AMR are
sought to be considerable and costly, it is difficult to
quantify precisely as the available data are usually in-
complete in many countries. The additional human
burdens associated with it (pain, change in daily
activities, psychosocial costs) are also inevitably signifi-
cant [6].
Low-income countries are also the least to regulate
drug distribution and utilization quality. The drug regu-
latory bodies have the responsibility of ensuring that
drug products dispensed to patients will provide the
necessary outcome and will not harm lies within the
healthcare system of a country. Quality assurance,
therefore, begins with licensing and monitoring of such
healthcare providers at all levels. While this is particu-
larly important for proper use of antimicrobials which
are in high demand in the countries with high infec-
tious disease burden including Ethiopia, there are find-
ings showing that the practice is generally poor leading
to the emergence of AMR pathogens [5, 7–10]. There-
fore, conducting drug use evaluation studies in country
like Ethiopia will have a profound importance in asses-
sing the extent of the problem and to respond to it in a
timely manner.
Detailed concerns in drug use evaluation may include
inappropriate drug selection, incorrect dose, prescrib-
ing drugs that cause ADRs or drug interactions, and
the use of expensive drugs when cheaper ones would
be possible. In recognizing this, WHO recommended
the alternative way of evaluating medicines utilization
pattern in a more rigorous manner in health facilities
to identify inappropriate uses and to promote rational
utilization of medicines through drug and therapeutic
committees [11].
A survey conducted in all regions of Ethiopia showed
that more than 70 % have had one or more antimicro-
bials prescribed in a range of 1-6 (and with an average
of 1.5) [12]. Ceftriaxone, as one of the most frequently
prescribed 3rd generation cephalosporin, with a reput-
able broad spectrum activity, relative low cost and
availability in many developing countries is highly
prone for misutilization [13, 14]. Few studies have eval-
uated the utilization of the drug in public hospitals of
Ethiopia. Studies conducted in Ethiopia (Black lion and
Police hospital, Ayder referral hospital, and Dessie ref-
eral hospital), revealed that there were inappropriate
use of ceftriaxone [15–17]. The purpose of the present
study, thus, is to evaluate the appropriateness of ceftri-
axone utilization in the medicine wards of general hos-
pitals in Addis Ababa, with reference to the standard
treatment guideline of Ethiopia for general hospitals.
Methods
Study setting
The study was conducted in the medicine wards of
Hayat and Zewditu memorial hospital. Hayat hospital is
a privately owned general hospital located in Bole sub-
city, Addis Ababa. It is established in 1999 and has a
total number of 70 beds with an average of 346 daily
patient flows. Hayat medical college is an affiliate of
the hospital that teaches in medicine and Bachelor of
Science in Nursing. The hospital also provides medical
services on payment to the general population including
referrals from nearby health institutions and regions.
Zewditu memorial hospital is also a public hospital
administered under health bureau of the city government
of Addis Ababa. Currently, the hospital has a total of 174
beds and provides referral medical services for patients
coming from all sub cities and remote areas out of Addis
Ababa. Established in 1932, Zewditu memorial hospital is
also affiliated with the oldest Nursing school. On average,
the hospital serves nearly 378 patients per day.
Study design
A retrospective cross sectional study design was con-
ducted to evaluate the utilization of ceftriaxone in Hayat
and Zewuditu memorial hospital from 20 January, 2014
to 20 February, 2014.
Inclusion and exclusion criteria
This study has included all the inpatients that have been
admitted to Hayat and Zewditu memorial hospital medi-
cine wards and stayed for more than 24 h. The patients
who had received at least one course of any dose of cef-
triaxone treatment within the twelve months prior to
the start of the data collection month were considered.
Medication records that had incomplete information in
main variables like Socio-demographic, drug related
traits, and diagnosis type were excluded.
Data abstraction format
Data collection format was developed based on the
WHO criteria [11] for Drug Use Evaluation, the manual
for Drug and Therapeutics Committee training course
by MSH and WHO [18] as well as the drug use evalu-
ation Criteria prepared by the American Society of
Health System Pharmacists [19]. The Ethiopian Standard
Treatment Guideline of 2010 for general hospitals [20]
was used to validate the tool for ceftriaxone in terms of
indication, dosage, frequency and duration of treatment.
Ceftriaxone treatment outcome measures were not con-
sidered since the study took a retrospective data.
Data collection procedure
Before the start of data collection, the codes (card num-
ber, age, gender, and name) and treatment dates of case
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records for all inpatients attended the medicine wards
were obtained from the patient registration documents.
The charts of patients treated with ceftriaxone were then
traced back to the records office of the hospitals using
the card numbers obtained from the inpatient registra-
tion documents. The traced patient records in the regis-
tration book were recorded chronologically on to a
separate form to include all the patient medication re-
cords. Data was collected for information on assessment,
sex, age, dose, frequency of administration, days of hos-
pital stay, number of co-morbid conditions, number and
type of co-prescribed drugs with ceftriaxone and dur-
ation of antibiotic therapy.
Ethical consideration
The study was approved by the School of Pharmacy
Research and Ethics committee, Addis Ababa University.
An approval and cooperation letter was also obtained
from the Addis Ababa health bureau written to each
hospital. The confidentiality of the data collected was
maintained and all patient direct and quasi-identifiers
(as name, address, phone number, card number, em-
ployer organization and name of relative…) were de-
identified.
Data analysis
The coded data were checked for completeness and en-
tered in to Statistical package for social sciences (SPSS)
version 20 for analysis. The WHO drug use evaluation
criteria set namely indication; dose, frequency and dur-
ation were used as major measurements against the
standard treatment guideline of Ethiopia. Inappropriate
use of ceftriaxone in the hospitals was determined by
comparing the observed ceftriaxone prescribing in the
chart records to the recommendations in the guideline.
A descriptive analysis was employed and results are
presented in tables and a figure. A binary logistic re-
gression was used to determine the association between
selected independent variables (age, sex, days of hos-
pital stay, number of co morbidity and number of drugs
co-prescribed) and the appropriate use of ceftriaxone.
Statistical significance was considered at 95 % confi-
dence interval.
Results
A total of 477 patient medication records (charts) from
both hospitals were included for analysis. Among these,
376 were from the public hospital and 101 were from
the private hospital. The proportion of ceftriaxone pre-
scription out of all medical ward admissions was 59 %
and 49 % in the public and the private hospital respect-
ively. From the 376 patients in the public hospital, 204
(54.3 %) were female. Of the 101 patients in the private
hospital, 68 (67.3 %) were male. Mean age of patients in
the public hospital was 44.6 years (±SD; 13.4) while in
the private hospital it was 49.8 years (±SD; 21.0). Major-
ity of treatment duration was in the range of 2–7 days
accounting for 76.6 % and 89.1 % of the public and pri-
vate hospital, respectively (Table 1). The median length
of hospital stay was 11 and 6 days in the public and pri-
vate hospital, respectively.
Common indications of ceftriaxone in the hospitals
Ceftriaxone was commonly utilized for pneumonia,
meningitis, sepsis and non-surgical prophylaxis in both
hospitals. It was also prescribed for hepatic disorders,
UTI, cellulitis, and diabetic foot ulcer, in the public hos-
pital. Similarly in the private hospital, ceftriaxone was in-
dicated commonly for hepatic disorders, Urinary Tract
Infection (UTI), cellulitis, diabetic foot ulcer, and Acute
Gastro Enteritis (AGE) (Table 2).
Frequently co-administered drugs with ceftriaxone in the
hospitals
Among the drugs co-administered with ceftriaxone, main-
tenance fluids took the lead in both hospitals, the propor-
tion being twofold in the private hospital compared to the
public hospital (72.28 % vs. 35.37 %). Metronidazole and
anti-TBs in the public hospital whereas diclofenac and
metoclopramide in the private hospital was the other
common co-prescribed drugs (Table 3).
Overall STG compliance of ceftriaxone therapy
One hundred ninety two of the 376 patients’ charts
(48.9 %) in the public hospital were found to be comply-
ing for an overall evaluation of indication, dose, and fre-
quency of administration and duration of ceftriaxone
treatment according to the 2010 Standard Treatment
Table 1 Age, gender distribution and length of stay of patients
in the medicine wards of general hospitals in Addis Ababa,
January, 2014 (n = 477)
Hospital
Public Private
N % N %
Age (Years)
14-65 329 87.5 73 72.3
>65 47 12.5 28 27.7
Gender
Male 172 45.7 68 67.3
Female 204 54.3 33 32.7
Length of stay
0-7 days 110 29.2 76 75.2
8-14 days 133 35.4 17 16.8
>14 days 133 35.4 8 8.0
Total 376 100.0 101 100.0
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Guideline (STG) of Ethiopia for general hospitals. Using
a similar procedure, 45 of the 101 patients (44.6 %) who
were administered with ceftriaxone in the private hos-
pital were found to comply with the guideline.
Of the total 192 patient charts identified as inappropri-
ate in the public hospital, 86 (44.8 %) was wrong indica-
tion of ceftriaxone as per the guideline whilst in 106
(55.2 %) cases were noted to show differences in dose,
route, frequency or duration of administration between
practice and the Guideline (Fig. 1). Wrong uses of
ceftriaxone in the assessments of hepatic disorders,
non-surgical prophylaxis, abscess, Chronic Obstructive
Pulmonary Disease (COPD), wound, gastroenteritis,
Bronchitis and upper gastro intestinal bleeding for
which the guideline recommends no indication of the
drug was noticed in the study.
In addition, deviation in duration of treatments for
pneumonia, sepsis, meningitis, UTI, cellulitis and dia-
betic foot ulcer were noted (Table 2). Other than dur-
ation, appropriate doses were not mentioned in the
treatment of pneumonia, meningitis, and sepsis.
Factors associated with STG compliant use of ceftriaxone
From the results of the binary logistic regression, it was
found that the likelihood of appropriate ceftriaxone use
increased with days of hospital stay in both the public and
the private hospital (AOR = 6.00; 95 % CI [3.40–10.80]),
(AOR = 3.30; 95 % CI, [1.00–9.12]). This association works
even when days of hospital stay increase beyond 14 days
in the public hospital (AOR = 5.58; 95 % CI, [3.10–10.00])
while it failed to show statistical significance in the private
hospital (AOR = 3.50; 95 % CI, [0.75–16.58]). Other
variables namely, age, sex, co morbidity and presences
of co administered drugs were not associated with ap-
propriateness (Table 4).
Table 2 The most common diseases for which ceftriaxone was
prescribed in the medicine wards of general hospitals in AA,
February, 2014 (n = 477)
Public hospital Private hospital




Diagnoses N N (%) N N (%)
Pneumonia 152 105(69.1) 24 13(54.2)
Meningitis 62 47(75.8) 13 11(84.6)
Sepsis 50 22(44) 13 11(84.6)
Non-surgical
prophylaxis
32 0 7 0
Hepatic disorders 17 0 5 0
UTI 16 0 8 2(25)
Cellulitis 12 3(25) 1 1(100)
Diabetic foot ulcer 9 6(66.7) 4 2(50)
Abscess 8 0 -
COPD 4 0 -
Wound 4 0 -
AGE 3 0 5 0
Pelvic inflammatory
diseases
2 1(100) 5 1(20)
STDs 2 0 -
Bronchitis 1 0 5 0
Typhoid fever 1 0 6 4(66.7)
Upper GI bleeding 1 0 -
PUD - - 1 0
Tonsillitis - - 3 0
Epididymitis - - 1 0
Total 376 184(48.9) 101 45(44.6)
Table 3 The most frequently co-administered drugs with ceftriaxone in the medicine wards of general hospitals in AA, February,
2014 (n = 477)
Public hospital (N = 376) Private hospital (N = 101)
Drug Frequency Percent Drug Frequency Percent
Maintenance fluids 133 35.37 Maintenance fluids 73 72.28
Metronidazole 124 32.98 Diclofenac 36 35.64
Anti-TBs 93 24.73 Methochlopramide 22 21.78
Cimetidine 77 20.48 Anti-Diabetics 18 17.82
Azithromycin 68 18.09 Tramadol 17 16.83
Furosemide 66 17.55 Vitamin B complex 16 15.84
Dexamethasone 62 16.49 Metronidazole 13 12.87
Cotrimoxazole 55 14.63 Quinine 9 8.91
Tramadol 52 13.83 Anti-TBs 8 7.92
Heparin 50 13.30 Furosemide 8 7.92
Spironolactone 47 12.50 Esomeprazole 7 6.93
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Discussion
The extent of ceftriaxone utilization in the present study
was comparably different among the public and the pri-
vate hospital. A higher proportion (59.3 %) of the pa-
tients admitted to the medicine ward of the public
hospital have taken at least a single dose of the drug
compared to the private hospital (49 %) in the previous
one year. A higher figure was reported by a prospective
evaluation in a teaching hospital medicine ward of India
accounted for 72 % [21]. This higher figure could result
due to the shorter period of evaluation considered
(5 months). However, a lower result (34 %) was, also, re-
ported by another study in an educational hospital of
Tehran [22]. A prospective cross sectional study in the
tertiary care hospital of India [23] has shown an equiva-
lent proportion as the private hospital in this evaluation
with an amount of 48.5 %. This is probably because; the
proportion represents the percentage of patients in the
medicine ward who had been administered with only
ceftriaxone despite the utilization of other cephalosporin.
The variation in the extent of ceftriaxone utilization
among the public and the private hospital might be con-
tributed to the availability and use of different generations
of cephalosporin in the private hospital leading to lower
ceftriaxone consumption.
A higher proportion (48.9 %) of the charts in the pub-
lic hospital showed appropriate prescribing of ceftriax-
one relative to the private hospital (44.6 %). Though the
two hospitals were comparable in many aspects, this
difference might have been in effect by the availability of
DTC/DIC, hospital specific drug lists as well as the STG
of Ethiopia in the public hospital while all were absent
in the private hospital. These figures are lower as com-
pared to studies conducted inside the country [15, 17].
The reasons for the above difference could be the
shorter evaluation period affecting the overall compli-
ance level. Lower figures were also reported by similar
studies conducted in Ethiopia (Ayder referral hospital),
Iran, Australia, and Thailand [16, 22, 24, 25].
Majority (55.5 %) of the noncompliance to STG in
the public hospital were related to differences in dose,
route, frequency and duration of administration be-
tween practice and the guideline. At the same time,
prescribing of ceftriaxone for the treatments of hepatic
disorders, non-surgical prophylaxis and abscess which
are not mentioned in the guideline was also observed.
Higher proportions, (58.9 %), of noncompliance in the
private hospital were indication of ceftriaxone for non-
surgical prophylaxis, bronchitis, hepatic disorders and
tonsillitis. Noncompliance to the STG was observed in
the duration of treatment for pneumonia, pelvic in-
flammatory disease, typhoid fever and meningitis. In-
appropriate use of ceftriaxone for bronchitis was
reported in another study conducted inside the coun-
try [16]. The use of ceftriaxone for prophylaxis in high
risk non-surgical patients of the public hospital was
very high (32 %) compared to the case in the private
hospital (7 %).
Fig. 1 Proportion of Overall compliance use of ceftriaxone among medicine wards of general hospitals in AA, February, 2014 (n = 250)
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The most common inappropriate use of ceftriaxone
was deviation from the recommended treatment dur-
ation. This is complemented by most of the drug use
evaluation studies in Ethiopia which indicated duration
as a common deviation from the guideline, majorly in
the managements of pneumonia, meningitis and sepsis
[15–17]. A similar study in Thailand has also revealed
that duration and indication of ceftriaxone therapy were
main components of inappropriate use [25].
From the results of the binary logistic regression, it
was found that the appropriate use of ceftriaxone
increased with days of hospital stay in both the public
and the private hospital. Most of the inappropriate
medication uses in the medical patients arise due to
short duration of therapy than is recommended in the
guideline. Short durations, in turn and partly, arise
when the patients are not able to afford for admission
(bed) costs, medical and non-medical expenses for
most reasons. Though the median length of hospital
stay in the public hospital (11 days) was longer than
that in the private hospital (6 days) probably due to
costs mentioned above, it is evident that increased
Table 4 Factors associated with appropriateness of ceftriaxone utilization in the medicine wards of general hospitals in AA; February
2014 (n = 477)
Crude Adjusted
Factors N % OR 95 % CI OR 95 % CI
Public hospital Age
14–65 Yrs. 329 87.5 1.34 0.72–2.49 0.80 0.40–1.50
>65 Yrs. 47 12.5 1.00 1.00 1.00 1.00
Sex
Male 172 45.7 0.91 0.61–1.37 0.95 0.60–1.5
Female 204 54.3 1.00 1.00 1.00 1.00
Days of hospital stays
0–7 days 110 29.25 1.00 1.00 1.00 1.00
8–14 days 133 35.40 5.90 3.30–10.50 6.00 3.40–10.80
>14 days 133 35.40 5.710 3.20–10.15 5.58 3.10–10.00
Co morbidity
0 60 16.0 1.00 1.00 1.00 1.00
> = 1 316 84.0 1.68 0.95-2.95 1.60 0.89–3.00
Co-prescribed
0 6 1.6 1.00 1.00 1.00 1.00
> = 1 370 98.4 0.95 0.19–4.807 1.10 0.20–6.00
Private hospital Age
14–65 Yrs. 73 72.3 0.64 0.34–1.94 1.60 0.60–4.00
>65 Yrs. 28 27.7 1.00 1.00 1.00 1.00
Sex
Male 68 67.3 1.40 0.59–3.34 1.20 0.50–3.10
Female 33 32.7 1.00 1.00 1.00 1.00
Days of hospital stay
0–7 days 76 75.2 1.00 1.00 1.00 1.00
8–14 days 17 16.8 3.00 1.00–9.11 3.00 1.00–9.12
>14 days 8 8.0 3.61 0.80–16.37 3.50 0.75–16.58
Comorbidity
0 37 36.6 1.00 1.00 1.00 1.00
> = 1 64 63.4 1.50 0.65–3.55 1.23 0.48–3.20
Co-prescribed
0 2 2.0 1.00. 1.00 1.00 1.00
>1 99 98.0 0.63 0.03–10.30 0.38 0.02–6.73
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length of stay would alleviate deviations from proper
duration of therapy.
Pneumonia, meningitis and sepsis were common cases
in which ceftriaxone was prescribed in both hospitals.
Similar findings in Ethiopia were also reported that pneu-
monia, meningitis and sepsis are the top cases which cef-
triaxone was indicated [15–17]. This implies that these
diseases are prevalent and known to consume the drug in
most admissions of Ethiopian hospitals.
Among the drugs co-prescribed with ceftriaxone,
maintenance fluids ranked at the top in both hospitals in
which the proportion being a twofold in the private
hospital (72.28 % vs. 35.37 %). Metronidazole (32.98 %)
and anti-TBs (24.73 %) accounted the next high percent-
age of co-prescribed drugs in the public hospital whereas
diclofenac (35.64 %) and metoclopramide (21.78 %) oc-
cupied the same order in the private hospital. The overall
pattern in both hospitals showed that infectious diseases
were the major co morbidities followed by chronic disease
(Diabetes, hypertension, hyperlipidemia and stroke). Intra-
venous (IV) incompatibility could be a possible threat in
the study areas as maintenance fluids involving ringer
lactate were noted to be co-prescribed.
Limitations of the study
The evaluation was relied, merely, on the medication re-
cords of patients/charts for which the drug use by the
patient or administration by health care professional
might have, pragmatically, been different.
Conclusion
Ceftriaxone is one of the most commonly prescribed
drugs for treatment and prevention of a disease in both
hospitals. However, the use of the drug in a significant
number of cases was not in accordance to the Ethiopian
standard treatment guideline. Indication and duration of
ceftriaxone treatment were the aspects in which noncom-
pliance were frequently noted. Of factors considered, dur-
ation of hospital stay was found to be predictive for
appropriate use of this drug. Having strict antibiotic policy
and complete adherence to national and international
treatment guidelines may alleviate the problem.
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